Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial. - Wikidata - wikimedia - TriplyDB

Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.

Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.

http://www.wikidata.org/entity/Q33593103

about

Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity The duration of antigen-stimulation significantly alters the diversity of multifunctional CD4 T cells measured by intracellular cytokine staining Immune interventions in HIV infection.Tailored immunity by skin antigen-presenting cells.Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodes.New challenges in modern vaccinology Transcutaneous DNA immunization following waxing-based hair depilation elicits both humoral and cellular immune responses Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination.Particle based vaccine formulations for transcutaneous immunization Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D,L-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses.Towards a Chlamydia trachomatis vaccine: how close are we?Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy.Transdermal immunization: biological framework and translational perspectives.Transcutaneous vaccines--current and emerging strategies.Selective hair therapy: bringing science to the fiction.The role of microneedles for drug and vaccine delivery.Toward a cure for HIV--Seeking effective therapeutic vaccine strategies.New Horizons in the Development of Novel Needle-Free Immunization Strategies to Increase Vaccination Efficacy.Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial Langerhans Cells-Programmed by the Epidermis.Transfollicular delivery takes root: the future for vaccine design?Long-term maintenance of skin immune system in a NOD-Scid IL2rγnullmouse model transplanted with human skin

P2860

Q27309214-6DFB5969-502B-48E6-93A9-277C619D9598 Q31068532-9A202524-2962-4C09-9531-D863BAD5ECF4 Q34351326-A51413DE-FC29-4023-B316-F3508E714223 Q34452461-B9EDFC50-5212-47EE-A201-F7BA6C705A06 Q35138155-7A1483E0-9475-4D87-9246-5E40F438B0F7 Q35218614-5C1E16D2-0E0A-4391-93F4-562B39EFFA4B Q36227323-7E9D71BD-17E2-4279-A161-3B8AE25597A7 Q37184801-18BC2704-2471-431E-8BAE-7756118E88CC Q37530378-3EDE400C-029A-4C5D-AE67-9656A75016DA Q37607079-1D374F2B-2CEB-4BDC-AEC0-9DE86ED0CB07 Q37820669-9FC35890-27AC-4410-BFD5-D021E636BAB2 Q37999873-035EBD87-04BE-43F4-9D25-3C1C6ED8F8B4 Q38068975-DF4B4B9A-F59D-4F1C-ACA5-FA4A7B23B4DB Q38073800-B2CD02DD-EE2A-4F9B-BFA8-E47A90AFD2FD Q38175504-A92D291B-D2DA-40B0-8AE9-FBACF20F723A Q38229145-6A3AB9D7-8920-4E73-9327-BDDDBCD113E9 Q38626469-40320FB6-7EC2-440F-B2FC-040C2A5684D8 Q38883770-F413275D-3D46-4B2C-A03B-0BE852EFCC7B Q42376121-B8D3F94E-04B2-4E15-BE62-DF51667EC169 Q47109271-596F437A-AA16-46DE-9669-608896AB848A Q49116950-B7BCC51D-CFB0-4F1B-9607-D874647D320F Q56795500-B31A8CF4-43E1-449E-BF14-549086200907

P2860

Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.

http://www.wikidata.org/entity/Q33593103

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Preferential amplification of ...... e: a randomized phase I trial.

@ast

Preferential amplification of ...... e: a randomized phase I trial.

@en

type

label

Preferential amplification of ...... e: a randomized phase I trial.

@ast

Preferential amplification of ...... e: a randomized phase I trial.

@en

prefLabel

Preferential amplification of ...... e: a randomized phase I trial.

@ast

Preferential amplification of ...... e: a randomized phase I trial.

@en

P1433

Q33593103-AD3C7A35-88B3-490B-AF1E-D3826865881B

P1476

Q33593103-58FE4B74-6F31-4A50-AC09-2CFDB14FDAD1

P2093

Q33593103-08786517-995B-489B-BCA6-8B5C34FEBA6E

Q33593103-27405128-70BE-4D93-813D-7CEF35AEE798

Q33593103-65C7263B-4D36-4274-8D13-07C70AC1B3E2

Q33593103-728173F0-B6C3-4FE9-A618-E25FB9899D57

Q33593103-8DCAA442-FD35-4323-9091-34AB22A3E1AE

Q33593103-B82519F1-E222-4CD5-8297-547A2FE73B5C

Q33593103-B8D99389-FA95-4D3A-8883-083B628105DC

Q33593103-C0040D1B-7EE7-4769-AE4F-A601D8F734CF

Q33593103-D4C48B0B-6D3B-47D3-966E-F6F600EC7576

P2860

Q33593103-006FEB95-2ACB-48A4-9574-F24F5A9462D6

Q33593103-02931D3B-A722-42BB-BDA2-927647330FE8

Q33593103-02959F6C-D8DF-45CF-A457-3F00BD88A2B9

Q33593103-124542E1-C6E4-4084-9ADA-84A2B46EC548

Q33593103-148905CB-CFD7-4050-8D70-BD6C19950FAF

Q33593103-159D496C-2D78-4667-BD91-A679036E85B8

Q33593103-19302C8E-5406-44F5-AC14-6476A762F9A2

Q33593103-23A1A59D-B57A-4BBB-B8DE-F93589FCF95C

Q33593103-285D5FBA-2CEE-4214-8B34-1C72A46C3739

Q33593103-28AD209A-DC79-45F9-87CA-6299AB96088D

P304

Q33593103-EC606839-6DAF-4D40-BAE1-AB2B853C49B2

P31

Q33593103-2B10B598-8211-42C4-9BDC-9139127A395C

P356

Q33593103-A5695FB3-D4BF-42DE-A754-83AF6D40AAE0

P407

Q33593103-DA7949E9-CC50-44EF-A261-18999C5879E2

P433

Q33593103-59320BEF-8B51-4DCE-95F9-5C338B196477

P478

Q33593103-E0A9AABC-AB97-4EB2-A16C-574445AB50F8

P50

Q33593103-0CD83091-ED74-4C8C-86F0-91DC3D8A1E66

Q33593103-30242016-E13D-49FA-8B17-921A97B87FA9

Q33593103-6FEB24E6-91C3-4706-9DFA-81FD1345E8A7

Q33593103-767CCF60-2D4B-4883-9803-C04702A0C563

Q33593103-F832F270-6690-4CA9-A042-9FEFF27D656E

Q33593103-FFC0CC1F-5E7A-4601-836B-66F372324111

P577

Q33593103-66B07D78-72E9-405F-B255-3D9065806AED

P5875

Q33593103-6D20CE95-2DA8-4EF3-A9CA-D1A8353CBFDC

P698

Q33593103-3D81F6CE-6F6B-47C6-B221-B8E83C318C3F

P921

Q33593103-19371F73-7655-4E80-A860-3E73302EF652

P932

Q33593103-00E6AB2C-D767-4ECE-80E3-5E5174ADEE16

P356

JOURNAL.PONE.0010818

P1433

P1476

Preferential amplification of ...... e: a randomized phase I trial.

@en

P2093

Annika Vogt

http://www.w3.org/2001/XMLSchema#string

Behazine Combadière

http://www.w3.org/2001/XMLSchema#string

Brice Mahé

http://www.w3.org/2001/XMLSchema#string

Hans Schaefer

http://www.w3.org/2001/XMLSchema#string

Olivia Bonduelle

http://www.w3.org/2001/XMLSchema#string

Sabrina Hadam

http://www.w3.org/2001/XMLSchema#string

Shlomo Staszewski

http://www.w3.org/2001/XMLSchema#string

Ulrike Blume-Peytavi

http://www.w3.org/2001/XMLSchema#string

Wolfram Sterry

http://www.w3.org/2001/XMLSchema#string

P2860

The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides

Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population

Dendritic cells and the control of immunity

Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch

40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin

Differential antigen processing by dendritic cell subsets in vivo

T-cell quality in memory and protection: implications for vaccine design

Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).

Mass vaccination: solutions in the skin.

Use of adenovirus in vaccines for HIV.

P304

e10818

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0010818

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Brigitte Autran

Dominique Costagliola

Sylvie van der Werf

Christine Katlama

Ulrike Blume-Peytavi

Sylvie van der Werf

P577

2010-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44646943

http://www.w3.org/2001/XMLSchema#string

P698

20520820

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

2877091

http://www.w3.org/2001/XMLSchema#string